Does semaglutide reduce heart attack and stroke risk?
In SELECT, semaglutide reduced major cardiovascular events in adults with existing cardiovascular disease and overweight or obesity who did not have diabetes. The result applies to that studied population; it is not a promise of heart protection for everyone taking semaglutide.1
On this page
Who SELECT actually studied
SELECT was a randomized, double-blind trial of semaglutide against placebo. Participants were at least 45 years old, had a body mass index of at least 27 and already had cardiovascular disease. They had no history of diabetes. Those entry criteria are part of the answer, not a footnote to discard after reading the headline.1
This is evidence about reducing further cardiovascular events in people who already had disease. It is not a trial of prescribing semaglutide to every younger adult who wants to lose weight, or to everyone with a family history of heart disease. A benefit demonstrated in a specific group should be described with that group attached.
The intervention was weekly injected semaglutide in a trial with follow-up. A seller’s use of the word semaglutide does not establish that a different formulation or a compounded preparation has the same outcomes evidence. Product identity matters when a medical benefit is being used to explain a purchase.
What counted as an event
The main outcome was the first occurrence of cardiovascular death, a nonfatal heart attack or a nonfatal stroke. This is called a composite outcome because several different events count toward one primary result. It gives a clear test of the trial question, but it does not mean each individual component changed by exactly the same amount.1
Among 8,803 people assigned to semaglutide, 569 had a primary-outcome event, reported as 6.5%. Among 8,801 assigned to placebo, 701 did, reported as 8.0%. Mean follow-up was 39.8 months. These are trial-period outcomes, not annual event rates.1
The reported hazard ratio was 0.80, with a 95% confidence interval of 0.72 to 0.90. A hazard ratio compares the groups over time. It is not the same measure as subtracting the reported percentages, and it does not mean a participant had a 20% chance of avoiding an event.1
| Outcome | Semaglutide | Placebo |
|---|---|---|
| Primary cardiovascular event | 6.5% | 8.0% |
| Permanent discontinuation due to adverse events | 16.6% | 8.2% |
Lincoff et al., SELECT abstract. Mean follow-up 39.8 months. These outcomes measure different things.
Why relative and absolute results belong together
A headline that reports only a relative reduction leaves out the starting risk. A headline that reports only the event percentages can leave out the time-based analysis used by the trial. Reading both gives a more useful picture: fewer events occurred in the treatment group, over a particular follow-up period, in people already at elevated cardiovascular risk.
The figures cannot be turned into your personal risk by selecting whichever statistic sounds most reassuring. Your clinician needs to know your medical history, current medicines and reason for considering treatment. The trial supplies evidence for that conversation rather than replacing it.
The same caution applies to comparisons with other studies. A trial in people without established cardiovascular disease, or one with a different primary outcome, starts with a different question. Putting its percentage beside SELECT without explaining those differences can create a comparison the trials never made.
The treatment tradeoff
Adverse events that led to permanent discontinuation of the trial product were reported in 16.6% of the semaglutide group and 8.2% of the placebo group. That is a different outcome from a cardiovascular event. Both deserve a place in the explanation because a treatment can reduce an important health risk while being difficult for some people to continue.1
Not every symptom means the medication should be stopped, and this article supplies no stopping rule. Ask the prescriber what follow-up will be available if side effects make treatment hard. A provider comparison should explain how questions reach the prescribing team, rather than offering a reassuring slogan about support. The Wegovy side-effect rates describe a different trial population. If you are comparing follow-up services, our Ro review explains care access and separate medication charges; service features do not establish cardiovascular outcomes.
The study was funded by Novo Nordisk. Funding does not make a randomized result disappear, but naming it helps readers understand the evidence record. The trial’s design, outcomes and limitations still need to be assessed on their own.1
What to ask before using the result in a decision
Ask which approved product is being considered, which indication the clinician is treating and how your situation relates to the SELECT population. If a program emphasizes heart benefits, ask for the specific evidence behind its statement. An answer about general weight loss is not an answer about cardiovascular outcomes.
Insurance is another separate question. A published trial can explain why a treatment may be clinically relevant; it does not establish what your plan covers. Ask the plan about the prescribed product and indication, then ask the provider who handles any authorization work.
SELECT gives a substantive reason to discuss semaglutide beyond weight change. Its strongest use is a carefully matched conversation about a person with established cardiovascular disease, rather than a general wellness claim applied to every potential buyer.
Read next
Sources
A reference, not medical advice, and not a substitute for your prescriber or pharmacist. If you think you are having a medical emergency, call your local emergency number.